JP2014521623A5 - - Google Patents

Download PDF

Info

Publication number
JP2014521623A5
JP2014521623A5 JP2014522067A JP2014522067A JP2014521623A5 JP 2014521623 A5 JP2014521623 A5 JP 2014521623A5 JP 2014522067 A JP2014522067 A JP 2014522067A JP 2014522067 A JP2014522067 A JP 2014522067A JP 2014521623 A5 JP2014521623 A5 JP 2014521623A5
Authority
JP
Japan
Prior art keywords
amino
pyrazol
pyrimidin
chloro
hydroxyethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014522067A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521623A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/064515 external-priority patent/WO2013014162A1/en
Publication of JP2014521623A publication Critical patent/JP2014521623A/ja
Publication of JP2014521623A5 publication Critical patent/JP2014521623A5/ja
Pending legal-status Critical Current

Links

JP2014522067A 2011-07-28 2012-07-24 Jak阻害剤としてのヘテロシクリルピリミジンアナログ Pending JP2014521623A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11175807.4 2011-07-28
EP11175807 2011-07-28
US201261635921P 2012-04-20 2012-04-20
US61/635,921 2012-04-20
PCT/EP2012/064515 WO2013014162A1 (en) 2011-07-28 2012-07-24 Heterocyclyl pyrimidine analogues as jak inhibitors

Publications (2)

Publication Number Publication Date
JP2014521623A JP2014521623A (ja) 2014-08-28
JP2014521623A5 true JP2014521623A5 (enExample) 2015-09-10

Family

ID=47600533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014522067A Pending JP2014521623A (ja) 2011-07-28 2012-07-24 Jak阻害剤としてのヘテロシクリルピリミジンアナログ

Country Status (9)

Country Link
US (1) US20140179664A1 (enExample)
EP (1) EP2736901A1 (enExample)
JP (1) JP2014521623A (enExample)
KR (1) KR20140047092A (enExample)
CN (1) CN103781780B (enExample)
AU (1) AU2012288892B2 (enExample)
BR (1) BR112014000360A2 (enExample)
CA (1) CA2843195A1 (enExample)
WO (1) WO2013014162A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6073677B2 (ja) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド 縮合複素環式化合物およびそれらの使用
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
CN105849099B (zh) 2013-10-18 2020-01-17 达纳-法伯癌症研究所股份有限公司 周期蛋白依赖性激酶7(cdk7)的多环抑制剂
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
EP3236959B1 (en) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP6861166B2 (ja) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド サイクリン依存性キナーゼの阻害剤
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
KR20250079249A (ko) 2015-10-08 2025-06-04 마크로제닉스, 인크. 암 치료를 위한 조합 치료법
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
CN109311857B (zh) 2016-06-16 2021-11-12 戴纳立制药公司 作为用于治疗神经退化性病症的lrrk2抑制剂的嘧啶-2-基氨基-1h-吡唑
CA3076276C (en) * 2017-09-21 2022-10-25 Beijing Scitech-Mq Pharmaceuticals Limited 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof
CN109535132B (zh) * 2017-09-21 2021-07-20 北京赛特明强医药科技有限公司 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
CA3099763A1 (en) 2018-06-25 2020-01-02 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
CN110734427B (zh) * 2018-07-20 2021-01-15 北京赛特明强医药科技有限公司 含烯基的嘧啶甲酰胺类化合物、组合物及其应用
CN110845476B (zh) * 2018-08-21 2022-11-18 上海和誉生物医药科技有限公司 一种高选择性csf1r抑制剂、其制备方法和在药学上的应用
WO2020097400A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
US12522583B2 (en) 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
WO2020097398A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020118683A1 (en) * 2018-12-14 2020-06-18 Lynk Pharmaceuticals Co. Ltd. Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
US12281126B2 (en) 2018-12-28 2025-04-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
SG11202112171XA (en) * 2019-05-10 2021-12-30 Deciphera Pharmaceuticals Llc Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
CN118930524A (zh) 2019-05-10 2024-11-12 德西费拉制药有限责任公司 苯基氨基嘧啶酰胺自噬抑制剂及其使用方法
AU2020297422B2 (en) 2019-06-17 2024-03-21 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
AU2020404305A1 (en) 2019-12-19 2022-08-04 Janssen Pharmaceutica Nv Substituted straight chain spiro derivatives
WO2024239282A1 (zh) * 2023-05-24 2024-11-28 凌科药业(杭州)有限公司 一种药物组合物、外用制剂及其制备方法、应用
WO2025157233A1 (zh) * 2024-01-26 2025-07-31 凌科药业(杭州)有限公司 一种吡唑基-氨基-嘧啶基衍生物的苯甲酰胺的晶型、制备方法及应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6111298A (en) 1997-02-12 1998-09-08 Samir M. Hanash Protein markers for lung cancer and use thereof
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
ES2308821T3 (es) 1997-12-15 2008-12-01 Astellas Pharma Inc. Nuevos derivados de pirimidin-5-carboxamida.
SK288138B6 (sk) 1999-02-10 2013-11-04 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
HU229414B1 (hu) 1999-11-05 2013-12-30 Astrazeneca Ab Kinazolin-származékok mint VEGF-inhibitorok, eljárás az elõállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NZ518884A (en) 1999-12-10 2004-02-27 Pfizer Prod Inc Pyrrolo[2,3-d]pyrimidine compounds
ATE369359T1 (de) 2000-02-15 2007-08-15 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
CN101218229A (zh) * 2005-05-05 2008-07-09 阿斯利康(瑞典)有限公司 吡唑基-氨基取代的嘧啶及其在癌症治疗中的应用
PL1891446T3 (pl) 2005-06-14 2013-08-30 Cellzome Gmbh Sposób identyfikacji nowych związków oddziałujących z enzymami
GB0605691D0 (en) 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
EP1862802B1 (en) 2006-06-01 2008-12-10 Cellzome Ag Methods for the identification of ZAP-70 interacting molecules and for the purification of ZAP-70
CA2657260A1 (en) 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
EP2099800A1 (en) 2006-11-16 2009-09-16 Pharmacopeia, LLC 7-substituted purine derivatives for immunosuppression
WO2008118822A1 (en) 2007-03-23 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7834024B2 (en) 2007-03-26 2010-11-16 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
ES2593486T3 (es) * 2007-04-18 2016-12-09 Pfizer Products Inc. Derivados de sulfonil amida para el tratamiento del crecimiento celular anómalo
TW200846344A (en) * 2007-04-25 2008-12-01 Astrazeneca Ab Chemical compounds
WO2009008992A2 (en) 2007-07-06 2009-01-15 Osi Pharmaceuticals Inc. Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
WO2010118986A1 (en) 2009-04-14 2010-10-21 Cellzome Limited Fluoro substituted pyrimidine compounds as jak3 inhibitors
KR20120102601A (ko) * 2009-10-20 2012-09-18 셀좀 리미티드 Jak 저해제로서의 헤테로시클릴 피라졸로피리미딘 유사체

Similar Documents

Publication Publication Date Title
JP2014521623A5 (enExample)
JP2015500862A5 (enExample)
JP2014531449A5 (enExample)
JP2013508332A5 (enExample)
RU2014130214A (ru) Пиримидин-2, 4-диаминовые производные в качестве ингибиторов киназы
RU2014152257A (ru) Гетероциклильные пиримидиновые аналоги в качестве ингибиторов tyk2
JP2016538313A5 (enExample)
RU2008135690A (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
JP2014526549A5 (enExample)
HRP20191220T1 (hr) Disupstituirani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora
RU2015101115A (ru) Гетероароматическое циклическое производное с алкильной разветвленной цепью
JP2017530999A5 (enExample)
JP2007519754A5 (enExample)
JP2014511869A5 (enExample)
HRP20172006T1 (hr) Derivati pirazol-aminopiridina kao lrrk2-modulatori
JP2014513694A5 (enExample)
RU2007132262A (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
JP2013531074A5 (enExample)
SI3074386T1 (en) New aminopyrimidine derivatives
IL263511A (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
RU2015121374A (ru) Ингибиторы alk-киназы
RU2013155456A (ru) Соединения пирролидинилмочевины и пирролидинилтиомочевины как ингибиторы киназы trka
JP2015517566A5 (enExample)
RU2016103938A (ru) Модуляторы протеин-тирозинкиназы и способы их применения
SI2790705T1 (en) Use of activity inhibitors or PI3K function